{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:52:43Z","timestamp":1759341163723,"version":"3.37.3"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1124\/jpet.120.265454","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T21:28:37Z","timestamp":1589491717000},"page":"283-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures"],"prefix":"10.1016","volume":"374","author":[{"given":"Etienne","family":"Guillot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Le Bail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Fourgous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Briand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Partiseti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Cornet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Janiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Philippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.120.265454_bib1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/j.1460-2075.1993.tb05814.x","article-title":"The probable arrangement of the helices in G protein-coupled receptors","volume":"12","author":"Baldwin","year":"1993","journal-title":"EMBO J"},{"key":"10.1124\/jpet.120.265454_bib2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1043-9471(05)80049-7","article-title":"Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors","volume":"25","author":"Ballesteros","year":"1995","journal-title":"Methods Neurosci"},{"key":"10.1124\/jpet.120.265454_bib3","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.2174\/1381612821666150216120500","article-title":"Analysis of Edg-like LPA receptor-ligand interactions","volume":"21","author":"Balogh","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1124\/jpet.120.265454_bib4","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1021\/ci034181a","article-title":"High-throughput modeling of human G-protein coupled receptors: amino acid sequence alignment, three-dimensional model building, and receptor library screening","volume":"44","author":"Bissantz","year":"2004","journal-title":"J Chem Inf Comput Sci"},{"key":"10.1124\/jpet.120.265454_bib5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1107\/S0907444998003254","article-title":"Crystallography & NMR system: a new software suite for macromolecular structure determination","volume":"54","author":"Br\u00fcnger","year":"1998","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1124\/jpet.120.265454_bib6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bbalip.2008.03.004","article-title":"Biological roles of lysophospholipid receptors revealed by genetic null mice: an update","volume":"1781","author":"Choi","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.120.265454_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev.pharmtox.010909.105753","article-title":"LPA receptors: subtypes and biological actions","volume":"50","author":"Choi","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.120.265454_bib8","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.cell.2015.06.002","article-title":"Crystal structure of antagonist Bound human lysophosphatidic acid receptor 1","volume":"161","author":"Chrencik","year":"2015","journal-title":"Cell"},{"key":"10.1124\/jpet.120.265454_bib9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/nu10040399","article-title":"Lysophosphatidic acid signaling in obesity and insulin resistance","volume":"10","author":"D\u2019Souza","year":"2018","journal-title":"Nutrients"},{"key":"10.1124\/jpet.120.265454_bib10","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1194\/jlr.M014985","article-title":"Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid","volume":"52","author":"Dusaulcy","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1124\/jpet.120.265454_bib11","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1016\/j.bmc.2008.04.035","article-title":"Identification of non-lipid LPA3 antagonists by virtual screening","volume":"16","author":"Fells","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/jpet.120.265454_bib12","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1124\/mol.63.6.1256","article-title":"The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints","volume":"63","author":"Fredriksson","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.120.265454_bib13","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.120.265454_bib14","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1021\/acs.jmedchem.9b01287","article-title":"A novel agonist of the type 1 lysophosphatidic acid receptor (LPA1), UCM-05194, shows efficacy in neuropathic pain amelioration","volume":"63","author":"Gonz\u00e1lez Gil","year":"2020","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.120.265454_bib15","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.120.265454_bib16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/meta.2001.21690","article-title":"Thiazolidinediones and glucocorticoids synergistically induce differentiation of human adipose tissue stromal cells: biochemical, cellular, and molecular analysis","volume":"50","author":"Halvorsen","year":"2001","journal-title":"Metabolism"},{"key":"10.1124\/jpet.120.265454_bib17","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00001756-200103260-00029","article-title":"Edg2 receptor distribution in adult rat brain","volume":"12","author":"Handford","year":"2001","journal-title":"Neuroreport"},{"key":"10.1124\/jpet.120.265454_bib18","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1038\/s41598-019-39041-4","article-title":"Molecular mechanism of lysophosphatidic acid-induced hypertensive response","volume":"9","author":"Kano","year":"2019","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.120.265454_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.yexcr.2014.11.020","article-title":"Lysophospholipid receptors in drug discovery","volume":"333","author":"Kihara","year":"2015","journal-title":"Exp Cell Res"},{"key":"10.1124\/jpet.120.265454_bib20","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1124\/mol.112.079699","article-title":"Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions","volume":"82","author":"Kiss","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.120.265454_bib21","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/nau.23955","article-title":"Effect of imipramine on urethral opening pressure: a randomized, double-blind, placebo-controlled crossover study in healthy women","volume":"38","author":"Kornholt","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1124\/jpet.120.265454_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00192-014-2512-9","article-title":"Pharmacological treatment of pure stress urinary incontinence: a narrative review","volume":"26","author":"Malallah","year":"2015","journal-title":"Int Urogynecol J"},{"key":"10.1124\/jpet.120.265454_bib23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0378-1119(94)90173-2","article-title":"Rapid isolation of highly productive recombinant Chinese hamster ovary cell lines","volume":"149","author":"Miloux","year":"1994","journal-title":"Gene"},{"key":"10.1124\/jpet.120.265454_bib24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/protein\/4.6.649","article-title":"Automated modeling of coiled coils: application to the GCN4 dimerization region","volume":"4","author":"Nilges","year":"1991","journal-title":"Protein Eng"},{"key":"10.1124\/jpet.120.265454_bib25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0014-5793(88)81148-7","article-title":"Determination of three-dimensional structures of proteins from interproton distance data by hybrid distance geometry-dynamical simulated annealing calculations","volume":"229","author":"Nilges","year":"1988","journal-title":"FEBS Lett"},{"key":"10.1124\/jpet.120.265454_bib26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0014-5793(88)80559-3","article-title":"Determination of three-dimensional structures of proteins from interproton distance data by dynamical simulated annealing from a random array of atoms. Circumventing problems associated with folding","volume":"239","author":"Nilges","year":"1988","journal-title":"FEBS Lett"},{"key":"10.1124\/jpet.120.265454_bib27","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1124\/mol.64.4.994","article-title":"Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors","volume":"64","author":"Ohta","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.120.265454_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-2000-6237","article-title":"Enantioselective sharpless dihydroxylation of vinylic aromatic heterocycles","volume":"1","author":"Philippo","year":"2000","journal-title":"Synthesis"},{"key":"10.1124\/jpet.120.265454_bib29","unstructured":"Philippo C, Auboussier S, Crespin O, Bovy P, Courtemanche G (1998a) inventors, Synthelabo, assignee. \u03b1-azacyclomethyl benzothiophene and \u03b1-azacyclomethyl benzofuran derivatives, preparation and therapeutic application. W.O. patent 33,793. 1998 Aug 6."},{"key":"10.1124\/jpet.120.265454_bib30","unstructured":"Philippo C, Orts MC, Crespin O, Bovy P (1998b) inventors, Synthelabo, assignee. Benzylamine derivatives, their preparation and their application in therapeutics. W.O. patent 08,834. 1998 Mar 5."},{"key":"10.1124\/jpet.120.265454_bib31","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1021\/jm034207p","article-title":"Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity","volume":"46","author":"Qian","year":"2003","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.120.265454_bib32","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/cmdc.200500042","article-title":"Phosphorothioate analogues of alkyl lysophosphatidic acid as LPA3 receptor-selective agonists","volume":"1","author":"Qian","year":"2006","journal-title":"ChemMedChem"},{"key":"10.1124\/jpet.120.265454_bib33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.biochi.2013.04.010","article-title":"Involvement of autotaxin\/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis","volume":"96","author":"Rancoule","year":"2014","journal-title":"Biochimie"},{"key":"10.1124\/jpet.120.265454_bib34","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1038\/mtna.2014.43","article-title":"Myelin basic protein and a multiple sclerosis-related MBP-peptide bind to oligonucleotides","volume":"3","author":"Rozenblum","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/jpet.120.265454_bib35","doi-asserted-by":"crossref","first-page":"e93230","DOI":"10.1371\/journal.pone.0093230","article-title":"A novel highly potent autotaxin\/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension","volume":"9","author":"Saga","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/jpet.120.265454_bib36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejphar.2019.01.014","article-title":"ASP6432, a type 1 lysophosphatidic acid receptor antagonist, reduces urethral function during urine voiding and improves voiding dysfunction","volume":"847","author":"Sakamoto","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.120.265454_bib37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1124\/jpet.118.247908","article-title":"Effect of ASP6432, a novel type 1 lysophosphatidic acid receptor antagonist, on urethral function and prostate cell proliferation","volume":"366","author":"Sakamoto","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.265454_bib38","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1194\/jlr.M039685","article-title":"Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice","volume":"54","author":"Salous","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1124\/jpet.120.265454_bib39","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1046\/j.1523-1755.2000.00322.x","article-title":"Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463","volume":"58","author":"Serradeil-Le Gal","year":"2000","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.120.265454_bib40","unstructured":"Shankar G, Solow-Cordero D, Spenser JV, Gluchowski C (2003) inventors, CERETEK LLC, assignee. Methods of treating conditions associated with an EDG receptor. W.O. patent 062,392. 2003 Jul 31."},{"key":"10.1124\/jpet.120.265454_bib41","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1074\/jbc.271.12.6941","article-title":"Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A","volume":"271","author":"Shire","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.120.265454_bib42","doi-asserted-by":"crossref","first-page":"14656","DOI":"10.1074\/jbc.M412585200","article-title":"Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2","volume":"280","author":"Simon","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.120.265454_bib43","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1021\/acsmedchemlett.6b00225","article-title":"Discovery of ONO-7300243 from a novel class of lysophosphatidic acid receptor 1 antagonists: from hit to lead","volume":"7","author":"Terakado","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/jpet.120.265454_bib44","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1194\/jlr.R046458","article-title":"LPA receptor signaling: pharmacology, physiology, and pathophysiology","volume":"55","author":"Yung","year":"2014","journal-title":"J Lipid Res"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.120.265454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:32:38Z","timestamp":1739964758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524258110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0022356524258110"],"URL":"https:\/\/doi.org\/10.1124\/jpet.120.265454","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.120.265454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}